医学
抗逆转录病毒疗法
人类免疫缺陷病毒(HIV)
抗逆转录病毒药物
抗逆转录病毒药物
药品
重症监护医学
大流行
疾病
抗药性
免疫学
病毒学
药理学
传染病(医学专业)
2019年冠状病毒病(COVID-19)
病毒载量
生物
内科学
微生物学
作者
Luis Menéndez‐Arias,Rafaël Delgado
标识
DOI:10.1016/j.tips.2021.10.004
摘要
Since the first cases of AIDS appeared in 1981, human immunodeficiency virus type 1 (HIV-1) infection has reached pandemic proportions. Forty years later, research has led to the approval of more than 30 antiretroviral drugs, while combination therapies have turned HIV-1 infection into a chronic, but manageable disease. Still, drug toxicity and acquired and transmitted drug resistance remain as major threats to therapy success. In this review, we provide an overview on currently available anti-HIV drugs and the latest developments in antiretroviral therapy, focused on new antiretroviral agents acting on known and unexploited antiviral targets, prevention therapies aimed to improve available drug combinations, and research on new long-acting therapies, particularly those involving novel drug candidates such as lenacapavir or islatravir.
科研通智能强力驱动
Strongly Powered by AbleSci AI